Patient data
Disease type and subject no. . | Age at SC or entry, y . | Follow-up, mo* . | HLA class I . | HLA class II . | CD4 T-cell number† . | Diagnosis . | Antiretroviral treatment‡ . |
|---|---|---|---|---|---|---|---|
| NHL | |||||||
| 68 | 43.5 | 12.4 | A29,A30,B18,B44 | DR7,DR14,DQ1,DQ2 | 850 | NHL | At 92 d before NHL (5, 6) |
| 139§ | 46.3 | 7.3 | A1,A2,B8,B51 | DR3,DR4,DQ2,DQ3, | 80 | NHL | — |
| 292 | 38.0 | 11.2 | A24,B16 | DRDR11,DR12,DQ3 | 210 | NHL | At diagnosis (1, 2, 5) |
| 308§ | 34.2 | 7.8 | A1,B8,B51 | DR1,DR17,DQ2,DQ5 | 100 | NHL | — |
| 354 | 35.2 | 6.1 | A1,A32,B7,B70 | DR4,DR15,DQ6,DQ7 | 30 | NHL | — |
| 434 | 48.9 | 13.1 | A2,A28,B7,B27 | DR6,DR9,DQ1 | 410 | NHL | 724 d before NHL (1, 5, 7) |
| 617 | 27.9 | 11.3 | A2,A11,B35,B62 | DR8,DR13,DQ1 | 390 | NHL | At diagnosis (5, 6, 7) |
| 6006§ | 41.8 | 6.3 | A2,A32,B7,B35 | DR11,DR17,DQ2,DQ7 | 50 | NHL | — |
| 8003 | 28.9 | 4.4 | ND | ND | 200 | NHL | — |
| Median | 38.0 | 7.8 | NA | NA | 200 | NA | NA |
| PROG | |||||||
| 53 | 27.3 | 7.1 | A1,A3,B39,B61 | DR1,DR11,DQ1,DQ3 | 140 | PCP | — |
| 232§ | 35.1 | 11.2 | A1,A3,B7,B8 | DR3,DQ2 | 150 | Mycobacteria | 3613 d after entry (3, 6, 7) |
| 341§ | 33.3 | 10.7 | A24,A28,B8,B13 | DR3,DR9,DQ2,DQ3 | 90 | PCP | 3533 d after SC (1, 5) |
| 495 | 37.6 | 4.6 | A1,B52,B60 | DR7,DR11,DQ1,DQ2 | 160 | Candida | — |
| Median | 34.2 | 8.9 | NA | NA | 145 | NA | NA |
| SP | |||||||
| 36§ | 34.9 | 9.3 | A1,A32,B8,B44 | DR3,DR12,DQ2,DQ3 | 450 | NA | 2224 d after SC (5, 6, 7) |
| 67 | 34.4 | 14.6 | A26,A28,B7,B57 | DR3,DR15,DQ2,DQ6 | 460 | NA | — |
| 750 | 31.7 | 17.6 | ND | ND | 380 | NA | — |
| 1160§ | 35.3 | 15.0 | A2,B8,B27 | DR,DR11,DQ2,DQ3 | 240 | NA | — |
| Median | 34.65 | 14.8 | NA | NA | 415 | NA | NA |
Disease type and subject no. . | Age at SC or entry, y . | Follow-up, mo* . | HLA class I . | HLA class II . | CD4 T-cell number† . | Diagnosis . | Antiretroviral treatment‡ . |
|---|---|---|---|---|---|---|---|
| NHL | |||||||
| 68 | 43.5 | 12.4 | A29,A30,B18,B44 | DR7,DR14,DQ1,DQ2 | 850 | NHL | At 92 d before NHL (5, 6) |
| 139§ | 46.3 | 7.3 | A1,A2,B8,B51 | DR3,DR4,DQ2,DQ3, | 80 | NHL | — |
| 292 | 38.0 | 11.2 | A24,B16 | DRDR11,DR12,DQ3 | 210 | NHL | At diagnosis (1, 2, 5) |
| 308§ | 34.2 | 7.8 | A1,B8,B51 | DR1,DR17,DQ2,DQ5 | 100 | NHL | — |
| 354 | 35.2 | 6.1 | A1,A32,B7,B70 | DR4,DR15,DQ6,DQ7 | 30 | NHL | — |
| 434 | 48.9 | 13.1 | A2,A28,B7,B27 | DR6,DR9,DQ1 | 410 | NHL | 724 d before NHL (1, 5, 7) |
| 617 | 27.9 | 11.3 | A2,A11,B35,B62 | DR8,DR13,DQ1 | 390 | NHL | At diagnosis (5, 6, 7) |
| 6006§ | 41.8 | 6.3 | A2,A32,B7,B35 | DR11,DR17,DQ2,DQ7 | 50 | NHL | — |
| 8003 | 28.9 | 4.4 | ND | ND | 200 | NHL | — |
| Median | 38.0 | 7.8 | NA | NA | 200 | NA | NA |
| PROG | |||||||
| 53 | 27.3 | 7.1 | A1,A3,B39,B61 | DR1,DR11,DQ1,DQ3 | 140 | PCP | — |
| 232§ | 35.1 | 11.2 | A1,A3,B7,B8 | DR3,DQ2 | 150 | Mycobacteria | 3613 d after entry (3, 6, 7) |
| 341§ | 33.3 | 10.7 | A24,A28,B8,B13 | DR3,DR9,DQ2,DQ3 | 90 | PCP | 3533 d after SC (1, 5) |
| 495 | 37.6 | 4.6 | A1,B52,B60 | DR7,DR11,DQ1,DQ2 | 160 | Candida | — |
| Median | 34.2 | 8.9 | NA | NA | 145 | NA | NA |
| SP | |||||||
| 36§ | 34.9 | 9.3 | A1,A32,B8,B44 | DR3,DR12,DQ2,DQ3 | 450 | NA | 2224 d after SC (5, 6, 7) |
| 67 | 34.4 | 14.6 | A26,A28,B7,B57 | DR3,DR15,DQ2,DQ6 | 460 | NA | — |
| 750 | 31.7 | 17.6 | ND | ND | 380 | NA | — |
| 1160§ | 35.3 | 15.0 | A2,B8,B27 | DR,DR11,DQ2,DQ3 | 240 | NA | — |
| Median | 34.65 | 14.8 | NA | NA | 415 | NA | NA |
SC indicates seroconversion; —, no antiretroviral treatment; ND, not done; PROG, progressor; PCP, Pneumocystis carinii pneumonia; SP, slow progressor; and NA, not applicable.
Time from entry or seroconversion to AIDS diagnosis or last time point of follow-up (for the slow progressors)
CD4 count at AIDS diagnosis or at least time point studied (slow progressors)
Antiretroviral therapy: 1 indicates zidovudine (zdv); 2, didanosine (ddI); 3, zalcitabine (ddC); 5, lamuvidine (3TC); 6, indinavir; and 7, saquinavir (HGC)
Individuals included in a previous study14